BioNTech SE Sponsored ADR (NASDAQ:BNTX) Receives Consensus Recommendation of "Moderate Buy" from Analysts

BioNTech SE Sponsored ADR (NASDAQ:BNTX - Get Free Report) has earned an average recommendation of "Moderate Buy" from the eighteen brokerages that are covering the stock, MarketBeat.com reports. Four investment analysts have rated the stock with a hold rating, thirteen have given a buy rating and one has issued a strong buy rating on the company. The average 1 year price target among brokers that have updated their coverage on the stock in the last year is $137.86.

BNTX has been the subject of a number of research analyst reports. Morgan Stanley cut their price target on BioNTech from $140.00 to $132.00 and set an "overweight" rating for the company in a report on Tuesday, May 6th. Wall Street Zen upgraded BioNTech from a "sell" rating to a "hold" rating in a report on Saturday, June 7th. The Goldman Sachs Group started coverage on BioNTech in a report on Thursday, May 29th. They set a "neutral" rating and a $110.00 price target for the company. Truist Financial restated a "buy" rating and issued a $155.00 target price (up from $151.00) on shares of BioNTech in a research note on Tuesday, June 3rd. Finally, Citigroup restated a "buy" rating and issued a $140.00 target price (down from $145.00) on shares of BioNTech in a research note on Tuesday, May 6th.

BioNTech Stock Up 0.1%

BioNTech stock opened at $111.78 on Thursday. The firm has a market cap of $26.87 billion, a price-to-earnings ratio of -32.88 and a beta of 1.29. The company has a debt-to-equity ratio of 0.01, a current ratio of 10.18 and a quick ratio of 10.02. BioNTech has a fifty-two week low of $76.53 and a fifty-two week high of $131.49. The firm has a fifty day moving average price of $103.17 and a two-hundred day moving average price of $106.86.

Institutional Trading of BioNTech

Large investors have recently made changes to their positions in the business. Bank of New York Mellon Corp grew its holdings in shares of BioNTech by 4.3% during the fourth quarter. Bank of New York Mellon Corp now owns 3,677 shares of the company's stock worth $419,000 after purchasing an additional 150 shares during the last quarter. Charles Schwab Investment Management Inc. grew its holdings in shares of BioNTech by 39.8% during the fourth quarter. Charles Schwab Investment Management Inc. now owns 187,355 shares of the company's stock worth $21,349,000 after purchasing an additional 53,319 shares during the last quarter. Raymond James Financial Inc. bought a new stake in shares of BioNTech during the fourth quarter worth $584,000. GAMMA Investing LLC grew its holdings in shares of BioNTech by 5,710.8% during the first quarter. GAMMA Investing LLC now owns 53,634 shares of the company's stock worth $4,884,000 after purchasing an additional 52,711 shares during the last quarter. Finally, Wealth Enhancement Advisory Services LLC bought a new stake in shares of BioNTech during the fourth quarter worth $238,000. Institutional investors own 15.52% of the company's stock.

About BioNTech

BioNTech SE, a biotechnology company, develops and commercializes immunotherapies for cancer and other infectious diseases. The company is developing FixVac product candidates, including BNT111, which is in Phase II clinical trial for advance melanoma; BNT112 that is in Phase I/IIa clinical trial for prostate cancer; BNT113, which is in Phase II clinical trial to treat HPV 16+ head and neck cancers; BNT114 to treat triple negative breast cancer; BNT115, which is in Phase I clinical trial in ovarian cancer; and BNT116, which is in Phase I clinical trial for non-small cell lung cancer.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.